肝病住院患者操作相关出血(PROC-BLeeD):一项国际前瞻性多中心观察性研究
该国际前瞻性多中心观察性研究纳入20个中心1187例接受3006次非外科操作的住院肝硬化患者,操作相关出血发生率为6.9%(按住院人次)和3.0%(按操作次数),大出血为2.3%和0.9%;高危操作、MELD评分和较高BMI独立预测出血,常规止血指标、术前预防性措施及近期抗血栓治疗与出血无关。
要点
- 住院肝硬化患者操作相关出血按住院人次为6.9%,按操作次数为3.0%,大出血分别为2.3%和0.9%。
- 高危操作(OR 4.64)、MELD评分(OR 2.37)和较高BMI(OR 1.40)独立预测出血。
- 术前INR、血小板水平和抗血栓药物使用未预测出血,出血患者28天死亡风险更高(HR 6.91)。
核心结论
- 住院肝硬化患者操作相关出血少见;BMI升高和失代偿肝病接受高危操作者可能有出血风险;出血与常规止血检测、术前预防或近期抗血栓治疗无关。
研究设计与样本
- 国际前瞻性多中心观察性研究,纳入20个中心1187例住院肝硬化患者,共接受3006次非外科操作,随访至手术、移植、死亡或入院后28天。
主要发现
- 共识别93例操作相关出血事件;出血按住院人次为6.9%、按操作次数为3.0%,大出血按住院人次为2.3%、按操作次数为0.9%。
- 出血患者较无出血患者更常见非酒精性脂肪性肝炎(43.9% vs 30%),BMI更高(31.2 vs 29.5),入院时MELD评分更高(24.5 vs 18.5)。
- 多变量分析控制中心间变异后,高危操作(OR 4.64;95%CI 2.44-8.84)、MELD评分(OR 2.37;95%CI 1.46-3.86)和较高BMI(OR 1.40;95%CI 1.10-1.80)独立预测出血。
- 术前INR、血小板水平和抗血栓药物使用未预测出血;出血患者更常接受出血预防(19.4% vs 7.4%)。
- 出血患者28天死亡风险显著更高(HR 6.91;95%CI 4.22-11.31)。
临床怎么用
- 原文未据此给出推荐;作者认为BMI升高和失代偿肝病接受高危操作的患者可能有出血风险,出血与常规止血检测、术前预防或近期抗血栓治疗无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hospitalized patients with cirrhosis frequently undergo multiple procedures. The risk of procedural-related bleeding remains unclear, and management is not standardized. We conducted an international, prospective, multicenter study of hospitalized patients with cirrhosis undergoing nonsurgical procedures to establish the incidence of procedural-related bleeding and to identify bleeding risk factors. METHODS: Hospitalized patients were prospectively enrolled and monitored until surgery, transplantation, death, or 28 days from admission. The study enrolled 1187 patients undergoing 3006 nonsurgical procedures from 20 centers. RESULTS: A total of 93 procedural-related bleeding events were identified. Bleeding was reported in 6.9% of patient admissions and in 3.0% of the procedures. Major bleeding was reported in 2.3% of patient admissions and in 0.9% of the procedures. Patients with bleeding were more likely to have nonalcoholic steatohepatitis (43.9% vs 30%) and higher body mass index (BMI; 31.2 vs 29.5). Patients with bleeding had a higher Model for End-Stage Liver Disease score at admission (24.5 vs 18.5). A multivariable analysis controlling for center variation found that high-risk procedures (odds ratio [OR], 4.64; 95% confidence interval [CI], 2.44-8.84), Model for End-Stage Liver Disease score (OR, 2.37; 95% CI, 1.46-3.86), and higher BMI (OR, 1.40; 95% CI, 1.10-1.80) independently predicted bleeding. Preprocedure international normalized ratio, platelet level, and antithrombotic use were not predictive of bleeding. Bleeding prophylaxis was used more routinely in patients with bleeding (19.4% vs 7.4%). Patients with bleeding had a significantly higher 28-day risk of death (hazard ratio, 6.91; 95% CI, 4.22-11.31). CONCLUSIONS: Procedural-related bleeding occurs rarely in hospitalized patients with cirrhosis. Patients with elevated BMI and decompensated liver disease who undergo high-risk procedures may be at risk to bleed. Bleeding is not associated with conventional hemostasis tests, preprocedure prophylaxis, or recent antithrombotic therapy.
引用
- Intagliata NM, Rahimi RS, Higuera-de-la-Tijera F, et al. Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study. Gastroenterology. 2023. PMID: 37271290. doi:10.1053/j.gastro.2023.05.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。